Table 3.
Gene amplification quantification relative to the SSTR2 reference genea
| Gene | Number of patients (%) (n = 86) |
Median (range) |
|---|---|---|
| MED1 | ||
| Deletion | 3 (3.5%) | 0.5 (0.5 to 0.5) |
| Normal | 27 (31.4%) | 0.9 (0.6 to 1.9) |
| Amplification | 56 (65.1%) | 4.6 (2 to 27.8) |
| Total | 86 (100.0%) | 2.6 (0.5 to 27.8) |
| STARD3 | ||
| Deletion | 0 | - |
| Normal | 6 (7.0%) | 1.5 (0.7 to 1.9) |
| Amplification | 80 (93.0%) | 6.4 (2.0 to 74.9) |
| Total | 86 (100.0%) | 5.9 (0.7 to 74.9) |
| HER2 | ||
| Amplification | 86 (100.0%) | 6.4 (2 to 32) |
| GRB7 | ||
| Deletion | 0 | - |
| Normal | 2 (2.3%) | 1.1 (0.6 to 1.7) |
| Amplification | 84 (97.7%) | 6.8 (2.3 to 36.5) |
| Total | 86 (100.0%) | 6.6 (0.6 to 36.5) |
| THRA | ||
| Deletion | 1 (1.2%) | 0.5 |
| Normal | 38 (44.2%) | 1.1 (0.6 to 1.9) |
| Amplification | 47 (54.7%) | 4.4 (2.0 to 11.7) |
| Total | 86 (100.0%) | 2.2 (0.5 to 11.7) |
| RARA | ||
| Deletion | 3 (3.5%) | 0.5 (0.4 to 0.5) |
| Normal | 60 (69.8%) | 1.0 (0.6 to 1.9) |
| Amplification | 23 (26.7%) | 3.4 (2.0 to 11.1) |
| Total | 86 (100.0%) | 1.1 (0.4 to 11.1) |
| TOP2A | ||
| Deletion | 4 (4.7%) | 0.5 (0.5 to 0.5) |
| Normal | 59 (68.6%) | 1.0 (0.6 to 1.8) |
| Amplification | 23 (26.7%) | 3.2 (2 to 7) |
| Total | 86 (100.0%) | 1.1 (0.5 to 7) |
| IGFBP4 | ||
| Deletion | 5 (5.8%) | 0.5 (0.5 to 0.5) |
| Normal | 63 (73.3%) | 1.0 (0.6 to 1.9) |
| Amplification | 18 (20.9%) | 3.1 (2 to 8) |
| Total | 86 (100.0%) | 1.1 (0.5 to 8) |
| CCR7 | ||
| Deletion | 3 (3.5%) | 0.4 (0.4 to 0.5) |
| Normal | 65 (75.6%) | 0.9 (0.6 to 1.8) |
| Amplification | 18 (20.9%) | 3.3 (2 to 14.9) |
| Total | 86 (100.0%) | 1.0 (0.4 to 14.9) |
| KRT20 | ||
| Deletion | 2 (2.3%) | 0.5 (0.5 to 0.5) |
| Normal | 72 (83.7%) | 1.1 (0.6 to 1.8) |
| Amplification | 12 (14.0%) | 3.1 (2.3 to 11.6) |
| Total | 86 (100.0%) | 1.1 (0.5 to 11.6) |
| KRT19 | ||
| Deletion | 5 (5.8%) | 0.5 (0.5 to 0.5) |
| Normal | 71 (82.6%) | 1.0 (0.6 to 1.8) |
| Amplification | 10 (11.6%) | 3.0 (2 to 6.4) |
| Total | 86 (100.0%) | 1.0 (0.5 to 6.4) |
| GAS | ||
| Deletion | 2 (2.3%) | 0.5 (0.4 to 0.5) |
| Normal | 78 (90.7%) | 1.0 (0.6 to 1.7) |
| Amplification | 6 (7.0%) | 2.8 (2 to 14.4) |
| Total | 86 (100.0%) | 1.0 (0.4 to 14.4) |
aAmplification: target gene/SSTR2 ratio ≥2; deletion: target gene/SSTR2 ratio ≤0.5; normal: 0.5 < target gene/SSTR2 ratio <2. MED1, mediator complex subunit 1 gene; STARD3, steroidogenic acute regulatory-related lipid transfer (START) domain containing 3 gene; HER2, human epidermal growth factor receptor 2 gene; GRB7, growth factor receptor-bound protein 7 gene; THRA, thyroid hormone receptor α gene; RARA, retinoic acid receptor α gene; TOP2A, topoisomerase IIα gene; IGFBP4, insulin-like growth factor-binding protein 4 gene; CCR7, C-C chemokine receptor type 7 gene; KRT20, cytokeratin 20 gene; KRT19, cytokeratin 19 gene; GAS, gastrin gene; SSTR2, somatostatin receptor type II gene.